🇺🇸 FDA
Patent

US 12281136

Crystalline forms of a CD73 inhibitor and uses thereof

granted A61KA61K31/706A61K45/06

Quick answer

US patent 12281136 (Crystalline forms of a CD73 inhibitor and uses thereof) held by Arcus Biosciences, Inc. expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arcus Biosciences, Inc.
Grant date
Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/706, A61K45/06, A61P, A61P35/00